phosphorylcholine has been researched along with abt-737 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shen, J; Xu, L; Zhao, Q | 1 |
| Adamová, B; Beneš, P; Navrátilová, J; Pokludová, J; Říhová, K; Šmarda, J | 1 |
2 other study(ies) available for phosphorylcholine and abt-737
| Article | Year |
|---|---|
Perifosine and ABT-737 synergistically inhibit lung cancer cells in vitro and in vivo.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Nitrophenols; Phosphorylcholine; Piperazines; Sulfonamides; Treatment Outcome | 2016 |
Synergistic cytotoxicity of perifosine and ABT-737 to colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Humans; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Tumor Microenvironment | 2023 |